Management of essential thrombocythemia

Critical Reviews in Oncology/Hematology

Volumn 29, Issue 3, 1999, Pages 257-266

  Barbui, Tiziano ^a   Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; CYTOTOXIC AGENT; HYDROXYUREA; NEW DRUG; PIPOBROMAN; RECOMBINANT ALPHA INTERFERON;

AMENORRHEA; BLEEDING; BONE MARROW APLASIA; CLINICAL TRIAL; ELECTIVE SURGERY; FEVER; FLU LIKE SYNDROME; HEART PALPITATION; HIGH RISK POPULATION; HUMAN; LEUKEMOGENESIS; LUNG FIBROSIS; MACROCYTIC ANEMIA; MYELODYSPLASIA; NEUTROPENIA; PREGNANCY; REVIEW; RISK FACTOR; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0032924168     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(98)00031-6     Document Type: Article

References (64)

1. Fialkow P.J., Faguet G.B., Jacobson R.J. et al. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent cell. Blood. 58:1981;916-919.
2. Kassar N.E., Hetet G., Li Y. et al. Clonal analysis of haemopoietic cells in essential thrombocythemia. Br J Haematol. 90:1995;131-137.
3. Murphy S. Therapeutic dilemmas: balancing the risk of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemostas. 78(1):1997;622-626.
4. Murphy S., Iland H.J. Thrombocytosis. Loscalzo J., Schafer A.L. Thrombosis and Hemorrhage. 1st ed. 1994;597-612 Williams and Wilkins, Baltimore.
5. Pearson T.C. Primary Thrombocythaemia: diagnosis and management. Br J Haematol. 78:1991;145-148.
6. Rozman C., Giralt M., Feliu E. et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 67:1991;2658-2663.
7. Murphy S., Iland H.J., Rosenthal D. et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol. 23:1986;177-182.
8. Murphy S., Peterson P., Iland H. et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol. 34:1997;29-39.
9. Dudley J.M., Messinezy M., Eridani S. et al. Primary thrombocythemia: diagnostic criteria and a simple scoring system for positive diagnosis. Br J Haematol. 71:1989;331-335.
10. Kutti J., Wadenvik H. Diagnostic and differential criteria of essential thrombocyhemia and reactive thrombocytosis. Leuk Lymphoma. 22(1):1996;41-45.
11. Sawyer B.M., Westwood N.B., Pearson T.C. Circulating megakaryocyte progenitor cells in patients with primary thrombocythemia and reactive thrombocytosis: results using a serum-deprived culture assay and positive detection technique. Eur J Hematol. 53:1994;108-113.
12. 9/l be used as a diagnostic criterion in essential thrombocythaemia ? An analyis of the natural course including early stages. Br J Haematol. 100:1998;15-23.
13. Landolfi R., Rocca B., Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit Rev Oncol Hematol. 20:1995;203-222.
14. Koudstaal P.J., Koudstaal A. Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. Semin Thromb Haemostas. 23(4):1997;365-370.
15. Van Genderen P.J.J., Michiels J.J. Erythromelalgia: a patognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Haemostas. 23(4):1997;357-364.
16. De Stefano V., Teofili L., Leone G. et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Haemostas. 23(5):1997;411-418.
17. Barbui T., Cortelazzo S., Viero P. et al. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol. 19:1983;1593-1599.
18. Bellucci S., Janvier M., Tobelem G. et al. Essential thrombocythemia: clinical evolutionary and biological data. Cancer. 58:1986;2440-2447.
19. Hehlmann R., Jahn M., Baumann B. et al. Essential thrombocythemia: clinical characteristics and course of 61 cases. Cancer. 61:1998;2487-2496.
20. Fenaux P., Simon M., Caulier M.T. et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 66:1990;549-556.
21. Colombi M., Radaelli F., Zocchi L. et al. Thrombotic and hemorrhagic complications in essential thrombocytemia. Cancer. 67:1991;2926-2930.
22. Finazzi G., Budde U., Michiels J.J. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma. 22(suppl. 1):1996;71-78.
23. Rinder H.M., Schuster J.E., Rinder C.S. et al. Correlation of thrombosis with increased platelet turnover in thrombocytosis. Blood. 91:1998;1288-1293.
24. Budde U., Scharf R.E., Franke P. et al. Elevated platelet count as a cause of abnormal von Willebrand factor multimer distribution in plasma. Blood. 82:1993;1749-1757.
25. Van Genderen P.J.J., Michiels J.J., van der Poel-van de Luytgaarde S.C.P.A.M. et al. Acquiredvon Willebranddisease as a cause of recurrent mucocutaneous bleeding in primary thrombocythemia: relationship with platelet count. Ann Hematol. 69:1994;81-84.
26. Cortelazzo S., Viero P., Finazzi G. et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 8:1990;556-562.
27. Randi M.L., Fabris F., Rossi C. et al. Sex and age as prognostic factors in essential thrombocythemia. Haematologica. 77:1992;402-404.
28. McIntyre K., Hoagland H., Silverstein M. et al. Essential thrombocythemia in young adults. Mayo Clin Proc. 66:1991;149-154.
29. Mitus A.J., Barbui T., Shulman L.N. et al. Hemostatic complications in young patients with essential thrombocythemia. Am J Med. 88:1990;371-375.
30. Kutti J. The management of thrombocytosis. Eur J Haematol. 44:1990;81-88.
31. Schafer A.I. Essential thrombocythemia. Prog Hemost Thromb. 10:1991;69-96.
32. Tefferi A., Silverstein M.N., Hoagland H.C. Primary thrombocythemia. Semin Oncol. 22:1995;334-340.
33. Barbui T., Finazzi G., Dupuy E. et al. Treatment strategies in essential thrombocythemia. Leuk Lymphoma. 22(suppl. 1):1996;149-160.
34. Griesshammer M., Bangerter M., vanVliet H.H.D.M. et al. Aspirin in essential thrombocythemia: status quo and quo vadis. Semin Thromb Haemostas. 23(4):1997;371-378.
35. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
36. Kelly J.P., Kaufman D.W., Jurgelon J.M. et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet. 348:1996;1413-1416.
37. Pagliaro P., Arrigoni L., Muggiasca M.L. et al. Primary thrombocyhthemia and pregnancy. Treatment and outcome in fifteen cases. Am J Hematol. 53:1996;6-10.
38. Griesshammer M., Heimpel H., Pearson T.C. Essential thrombocythaemia and pregnancy. Leuk Lymphoma. 22(suppl. 1):1996;57-63.
39. Beressi A.H., Tefferi A., Silverstein M.N. et al. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 155:1995;1217-1222.
40. Shpilberg O., Shimon I., Sofer O. et al. Transient normal platelet count and decreased requirement for interferon during pregnancy in essential thrombocythemia. Br J Haematol. 92:1996;491-493.
41. Löfvenberg E., Walhlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 41:1988;375-381.
42. Cortelazzo S., Finazzi G., Ruggeri M. et al. Hydroxyurea in the treatment of patients with essential thrombocythemia at high risk of thrombosis: a prospective randomized trial. N Engl J Med. 332:1995;1132-1136.
43. Daoud M.S., Gibson L.E., Pittelkow M.R. Hydroxyurea dermopathy:a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol. 36:1997;178-182.
44. Best P., Daoud M.S., Pittelkow M.R. et al. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 128:1998;29-32.
45. Nand S., Stock W., Godwin J. et al. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Am J Hematol. 52:1996;42-46.
46. Löfvenberg E., Nordenson I., Walhlin A. Cytogenetic abnormalities and leukemic transformation in hydroxyurea-treated patients with Philadelphia chromosome negative chronic myeloproliferative disease. Cancer Genet Cytogenet. 49:1990;57-67.
47. Weinfield A., Swolin B., Westin J. Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol. 52:1994;134-139.
48. Sterkers Y., Preudhomme C., Lai J.-L. et al. Acute myeloid leukemia and myelodyslastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood. 91:1988;616-622.
49. Shibata K., Shimamoto Y., Suga K. et al. Essential Thrombocythemia terminating in acute leukemia with minimal myeloid differentiation. A brief review of recent literature. Acta Haematol. 91:1994;84-88.
50. Blickstein D., Aviram A., Luboshitz J. et al. BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients: clinical presentation. Blood. 90:1997;2768-2771.
51. Van de Pette J.E.W., Prochazka A.V., Pearson T.C. et al. Primary thrombocythemia treated with busulfan. Br J Haematol. 62:1986;229-237.
52. Berk P., Goldberg J., Donovan P. et al. Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols. Semin Hematol. 23:1986;132-143.
53. Haanen C, Mathe G for the EORTC. Treatment of polycythaemia vera by radioactive phosphorus or busulphan. Br J Cancer 1981;44:75-8.
54. Boivin P. Indications, procedure and results for the treatment of polycythemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol. 35:1993;491-498.
55. Brusamolino E., Canevari A., Salvaneschi L. et al. Efficacy trial of Pipobromasn in essential thrombocythemia: a study of 24 patients. Cancer Treat Reports. 68:1984;1339-1342.
56. Mazzucconi M.G., Francesconi M., Chistolini A. et al. Pipobroman therapy of essential thrombocythemia. Scand J Haematol. 37:1986;306-309.
57. Najean Y, Rain JD for the French Polycythemia Study Group. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-7.
58. Petti M.C., Spadea A., Avvisati G. et al. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years. Leukemia. 12:1998;869-874.
59. Lengfelder E., Griesshammer M., Hehlmann R. Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma. 22(suppl. 1):1996;135-142.
60. Tefferi A., Elliot M.A., Solberg L.A. Jr et al. New drugs in essential thrombocythemia and polycythemia vera. Blood Rev. 11:1997;1-7.
61. Tefferi A., Silverstein M.N., Petitt R.M. et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indication. Semin Thromb Hemost. 23(4):1997;379-384.
62. Petitt R.M., Silverstein M.N., Petrone M.E. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semi Hematol. 34(1):1997;51-54.
63. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
64. Barbui T., Finazzi G., Pearson T.C. The management of essential thrombocythaemia. Hematology. 2:1997;91-100.